
Is this your show? Claim this page
PodCred
The people behind this show
People get invited back because someone remembered they were great.
PodCred is the verified record of who made this show. A credit here means people who were there confirmed the work.
Hosts
Who is on this show?
Think of the guest you still think about. The producer who makes the host sound smart. The editor who saves every episode. If a name is missing here, that person is invisible everywhere.
Add a creditEpisodes
94 episodesEpisode 82: Dr. Natalie Ma on Building Virtual Humans to Predict Drug Safety
Send us Fan Mail After earning a PhD in molecular biology at Yale, Dr. Natalie Ma moved from the bench to the business side of science to tackle drug development’s biggest problem: roughly 90% of programs fail, often...
Episode 81: Mithril Medicine (Now Anthropic)
Send us Fan Mail In this episode of Petri Dish Perspectives, we explore Mithril Medicine, the one-person biotech that Anthropic just acquired and the story behind the man who built it. Cody Tranbarger spent six years...
Episode 80: Dr. Meesha Dogan on Using AI and Epigenetics to Detect Heart Disease Early
Send us Fan Mail After a two-generation family history of heart disease, Dr. Meesha Dogan set out to change how the disease is detected. As founder and CEO of Cardio Diagnostics, she built and commercialized what the...
October 2026: Biotech & Pharma NEWS Roundup
Send us Fan Mail Welcome to your essential overview of the global biotech and pharmaceutical landscape for October 2026! This month was defined by a wave of oncology approvals, a head-to-head data drop that reshuffled...
Episode 79: Endeavor Health
Send us Fan Mail In this episode of Petri Dish Perspectives, we explore Endeavor Health, the Chicago-area hospital system most Illinoisans have driven past but couldn’t name. Born from Evanston Hospital in 1891, grown...
Episode 78: Dr. Kristin Gleitsman on Using AI to Make Better Drug Development Decisions
Send us Fan Mail After years of building discovery engines inside diagnostics, Kristin Gleitsman has become one of the more skeptical voices in AI and biology. A Caltech chemistry PhD, Kristin built Veracyte’s Discovery...
Episode 77: Revolution Medicines
Send us Fan Mail In this episode of Petri Dish Perspectives, we explore Revolution Medicines, the precision oncology company that spent over a decade trying to drug one of cancer’s most notorious targets: RAS. With...
Episode 76: Dr. Avinash Jayaraman on Why Your Kid's Screen Time Is a Clinical Emergency
Send us Fan Mail After training as a physician, earning an MBA from Wharton, and co-founding Sonara Health, a digital health company that raised over $10 million from the NIH, VCs, Dr. Avinash Jayaraman could have gone...
September 2026: Biotech & Pharma NEWS Roundup
Send us Fan Mail Welcome to your essential overview of the global biotech and pharmaceutical landscape for September 2026! This month was defined by blockbuster dealmaking, historic FDA approvals, and a growing...
Episode 75: Hengrui
Send us Fan Mail In this episode of Petri Dish Perspectives, we explore Jiangsu Hengrui Pharmaceuticals, the Chinese pharma giant that started as a state-owned generic drug factory in 1970 and quietly became one of the...
Episode 74: Dr. John Murphy on Building an Audience
Send us Fan Mail After years of running a school on the rigid rhythm of bells, Dr. John Murphy walked away from K-12 education and into something he never trained for: performing history at bars. In this episode, John...
Episode 73: Anew Labs
Send us Fan Mail In this episode of Petri Dish Perspectives, we explore Anew Labs, the AI drug discovery company that emerged from one of the most unexpected places in biotech: ByteDance, the parent company of TikTok....
Episode 72: Dr. Elliot Justin on S3xual Wearable Health Tech
Send us Fan Mail After a career spent racing against the clock in emergency rooms, Dr. Elliot Justin found himself chasing a very different kind of vital sign, one most men never think to track. Before FirmTech, he...
Episode 71: Fate of Pharma M&A
Send us Fan Mail In this episode of Petri Dish Perspectives, we take a step back from individual companies to examine one of the most powerful forces shaping the pharmaceutical industry: M&A, licensing, and the global...
August 2026: Biotech & Pharma NEWS Roundup
Send us Fan Mail Welcome to your essential overview of the global biotech and pharmaceutical landscape for August 2026! This month was defined by major dealmaking, a resurgence in biotech financing, and growing...
Episode 70: Cellares
Send us Fan Mail In this episode of Petri Dish Perspectives, we explore Cellares, the biotech company trying to solve one of the biggest and least discussed challenges in cell therapy: how do you manufacture these...
Episode 69: Summit Therapeutics
Send us Fan Mail In this episode of Petri Dish Perspectives, we explore the remarkable rise of Summit Therapeutics, a biotech that transformed itself from an infectious-disease company into one of the most closely...
Episode 68: Guardant Health
Send us Fan Mail In this episode of Petri Dish Perspectives, we explore the story of Guardant Health, one of the companies leading the shift toward blood-based cancer detection and precision oncology. Founded by genomic...
Episode 67: Epic Systems
Send us Fan Mail In this episode of Petri Dish Perspectives, we explore the story of Epic Systems, the privately held healthcare technology company that has quietly built much of the digital infrastructure behind...
July 2026: Biotech & Pharma NEWS Roundup
Send us Fan Mail Welcome to your essential overview of the global biotech and pharmaceutical landscape for June 2026! This month was dominated by AI cementing itself as a core part of drug discovery, with partnerships...
Episode 66: Scribe Therapeutics
Send us Fan Mail In this episode of Petri Dish Perspectives, we explore the story of Scribe Therapeutics, one of genome editing's most ambitious companies aiming to move beyond first-generation CRISPR. Rather than...
Episode 65: Apogee Therapeutics
Send us Fan Mail In this episode of Petri Dish Perspectives, we explore the story of Apogee Therapeutics, one of biotech's newest immunology companies aiming to redefine autoimmune disease through next-generation...
Episode 64: Conception Bio
Send us Fan Mail In this episode of Petri Dish Perspectives, we explore the story of Conception Bio, one of the most ambitious biotechnology companies working at the intersection of stem cell biology, reproductive...
Episode 63: Enveda Biosciences
Send us Fan Mail In this episode of Petri Dish Perspectives, we explore the story of Enveda Biosciences, one of the most exciting AI-native biotech companies redefining how drugs are discovered. While most...
Episode 62: Isomorphic Labs
Send us Fan Mail In this episode of Petri Dish Perspectives, we explore the story of Isomorphic Labs, Alphabet's ambitious drug discovery company born out of DeepMind's groundbreaking work on AlphaFold. From solving one...
June 2026: Biotech & Pharma NEWS Roundup
Send us Fan Mail Welcome to your essential overview of the global biotech and pharmaceutical landscape for June 2026! This month was dominated by a relentless wave of strategic consolidation and "barbell" deal-making,...
Episode 61: Danaher
Send us Fan Mail In this episode of Petri Dish Perspectives, we explore how two brothers transformed a small industrial holding company into one of the most influential life sciences organizations in history. We dive...
Episode 60: Hims & Hers
Send us Fan Mail In this episode of Petri Dish Perspectives, we dive into the rise of Hims & Hers Health, the telehealth company that transformed direct-to-consumer healthcare and challenged traditional medicine....
Episode 59: Illumina
Send us Fan Mail In this episode of Petri Dish Perspectives, we dive into the remarkable story of Illumina, from a small sequencing startup born during the Human Genome Project era to the company that transformed DNA...
Episode 58: UnitedHealthcare
Send us Fan Mail In this episode of Petri Dish Perspectives, we dive into the remarkable rise of UnitedHealthcare and its parent company, UnitedHealth Group. From its origins in the 1970s managed care movement to...
May 2026: Biotech & Pharma NEWS Roundup
Send us Fan Mail Welcome to your essential overview of the global biotech and pharmaceutical landscape for May 2026! This month was dominated by a wave of aggressive cross-border M&A and strategic capital deployment, as...
Episode 57: 23andMe
Send us Fan Mail This week on Petri Dish Perspectives, we unpack the story of 23andMe, the company that turned saliva kits into one of the largest human genetic databases in the world and brought genomics out of...
Episode 56: Thermo Fisher
Send us Fan Mail This week on Petri Dish Perspectives, we’re diving into the story of Thermo Fisher Scientific, the company quietly powering nearly every corner of modern biotechnology. From its origins in scientific...
Episode 55: Alnylam
Send us Fan Mail From the discovery of RNA interference to the first FDA-approved gene-silencing therapy, this week on Petri Dish Perspectives, we dive into the story of Alnylam Pharmaceuticals, the company that turned...
Episode 54: All about 340B
Send us Fan Mail In this episode of Petri Dish Perspectives, we break down the 340B Drug Pricing Program, a little-known but massively influential policy shaping how hospitals, pharmacies, and drug manufacturers operate...
April 2026: Biotech & Pharma NEWS Roundup
Send us Fan Mail Welcome to your essential overview of the global biotech and pharmaceutical landscape for April 2026! This month was dominated by a high-stakes pivot toward oral obesity treatments, a massive...
Episode 53: CAR-T Therapies
Send us Fan Mail What if cancer treatment wasn’t a drug but a living, evolving system inside your body? In this episode, we break down one of the most revolutionary innovations in modern medicine: CAR-T cell therapy....
Episode 52: Daiichi Sankyo
Send us Fan Mail In this episode of Petri Dish Perspectives: Biotech Unleashed, we break down the rise of Daiichi Sankyo, a company that quietly transformed itself from a cardiovascular powerhouse into one of the most...
Episode 51: ImmunoGen
Send us Fan Mail In this episode of Petri Dish Perspectives: Biotech Unleashed, we dive into the 40+ year journey of ImmunoGen, a company that refused to give up on one of the most complex and misunderstood technologies...
Episode 50: Exact Sciences
Send us Fan Mail In this episode of Petri Dish Perspectives, we’re dissecting the "Phoenix of Biotech." On March 23, 2026, the era of Exact Sciences as an independent company officially ended with its massive $23...
Episode 49: AI in Pharma / Biotech
Send us Fan Mail In this episode, we explore the high-stakes reality of AI integration in the life sciences. We move past the speculative hype to examine the mechanical necessity of this shift, driven by soaring R&D...
March 2026: Biotech & Pharma NEWS Roundup
Send us Fan Mail Welcome to your essential overview of the global biotech and pharmaceutical landscape for March 2026! This month was dominated by by three massive themes: more AI integrations, M&A deals, and continued...
Episode 48: Ginkgo Bioworks
Send us Fan Mail In this episode of Petri Dish Perspectives, we unpack how Ginkgo Bioworks set out to industrialize biology. From its origins at MIT to building one of the most ambitious synthetic biology platforms in...
Episode 47: SUN Pharma
Send us Fan Mail From a small operation built on just ₹10,000 to a global pharmaceutical powerhouse, Sun Pharmaceutical Industries is one of the most compelling growth stories in modern biotech. In this episode of Petri...
Episode 46: Servier
Send us Fan Mail In this episode of Petri Dish Perspectives, we explore the remarkable history of Servier, France’s largest independent pharmaceutical company and one of the only major drugmakers owned by a non-profit...
Posts
No posts yet. Posts PETRI DISH PERSPECTIVES shares on PodSubs, and what it publishes on Substack, YouTube and its own site, will show here.

Subscribe
Be on the front line of the show
Everything PETRI DISH PERSPECTIVES sends its own people, first. Resources, announcements, behind the scenes, events, and giveaways, straight from the host. No account needed.
- The resources the host shares with subscribers
- Announcements before anyone else hears
- Behind the scenes from the team
- Events, invitations, and giveaways
- Only what the host sends, nothing else
Audio and video play straight from the show's own hosting. PodSubs stores and serves no media.
















